Domain Associates
Edit

Domain Associates

https://www.domainvc.com/
Last activity: 23.01.2024
Invests in categories: MedTechDevelopmentHealthTechProductHardwareBioTechDrugTechnologyDiagnosticsSkin
ABOUT Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on investing in life science companies that advance human health. Domain’s focused network, deep experience, and dependable reputation of this team have made it one of the top private-equity groups participating in healthcare investing. With $2.4 billion of capital under management, Domain invests in three major segments: pharmaceuticals, diagnostics, and medical devices. EXPERIENCE Domain has raised eight funds and has been involved in the formation of more than 250 portfolio companies. The partners of Domain have a total of close to 200 person-years of experience among them in the healthcare and venture capital industries. Representative past investments include Amgen, Amylin Pharmaceuticals, BiPar Sciences, Biosite, Dura Pharmaceuticals and Pharmion. Our companies have created a number of U.S. approved products that have advanced human health. LEADERSHIP We have developed innovative investment models, such as specialty pharma and Japanese in-licensing, which have proven successful and have been widely emulated in the life science industry. We are engaged in new collaborations, including Domain’s investments in Russia and China with Rusnano and Beijing Elite, respectively.
News
466
Portfolio
94
Mentions
79
Location: United States, New Jersey
Employees: 11-50
Founded date: 1985
Investment Type: Venture Capital
Investment Stage: Series B; Series C; Series D

Portfolio 94

DateNameWebsiteTotal RaisedLocation
01.08.2017Milestone ...milestonep...$190MCanada, Qu...
25.07.2017Sebaciasebacia.co...$68MUnited Sta...
19.05.2017Iterum The...iterumtx.c...$157M-
28.04.2017Epic Scien...epicscienc...$217MUnited Sta...
27.04.2017ChromaCode...chromacode...$88M-
-Sequent Me...sequentmed...$61.6M-
-Adastra Ph...adastrarx....--
-Aspen Neur...aspenneuro...$264MUnited Sta...
-Goodwell T...goodwellte...--
-Obalon The...obalon.com$56.5MUnited Sta...
Show more

News 466

DateTitleDescription
01.02.2022Fractyl Health Publishes Two-Year Durability Data After a Si... LEXINGTON, MA., February 1, 2022 - Fractyl Health, an organ-editing metabolic therapeutics company...
21.04.2021Antios Therapeutics Doses First Patients in SAVE 1, a Phase ... MENDHAM, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. (“Antios”) today annou...
24.02.2020Antios Therapeutics Announces Notice of Allowance for a U.S.... ATLANTA, Feb. 24, 2020 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-...
09.01.2020Omniome Closes $60 Million Series C Financing To Advance Nov... SAN DIEGO—January 9, 2020 – Omniome, Inc., developer of an innovative DNA sequencing platform capa...
12.12.2019Aspen Neuroscience Launches With $6.5 Million Seed Funding t... SAN DIEGO, Dec. 12, 2019 — Aspen Neuroscience, Inc. today announced its launch following a $6.5 mi...
09.12.2019Achillion Reports Positive Data from Phase 2 Study of Danico... BLUE BELL, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), ...
11.11.2019Achillion Announces Clearance of Investigational New Drug Ap... BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), ...
25.10.2019Bempedoic Acid Included in Top 10 Medical Innovations for 20... ANN ARBOR, Mich., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoi...
22.10.2019Obalon Announces First Patient Treatments at its First Compa... SAN DIEGO, CA, October 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a wei...
21.10.2019Veracyte Announces New Data Demonstrating That Envisia Genom... SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 21, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announ...
Show more

Mentions in press and media 79

DateTitleDescriptionSource
18.05.2020Seraphina Therapeutics Reveals Groundbreaking Fatty Acid Dis...Seraphina Therapeutics, Inc., announced today its Series A fundraise of $5.5 million, led by Domain ...vegconomis...
20.11.2019With echoes of Theranos, Truvian Sciences revives the dream ...A little over a year after the dissolution of the once high-flying blood testing startup Theranos, a...techcrunch...
01.08.2017Tekla Capital Joins $55M Series C for Milestone Pharmaceutic...Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today ann...citybizlis...
01.08.2017Domain Associates Joins $55M Series C for Milestone Pharmace...Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today ann...citybizlis...
25.07.2017Domain Associates Leads $20M Series D for SebaciaSebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, t...citybizlis...
21.05.2017Iterum Raises $65M Series BIterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the developme...citybizlis...
21.05.2017Domain Associates Joins $65M Series B for IterumIterum Therapeutics Limited, an Irish clinical-stage pharmaceutical company focused on the developme...citybizlis...
30.04.2017Domain Associates Joins $40M Series D for Epic SciencesEpic Sciences (Epic) announced today that the company has completed a $40 million Series D financing...citybizlis...
27.04.2017NEA Leads $12M Series B for ChromaCodeChromaCode, Inc., a molecular diagnostics company, today announced it has raised $12 million in Seri...citybizlis...
27.04.2017Domain Associates Joins $12M Series B for ChromaCodeChromaCode, Inc., a molecular diagnostics company, today announced it has raised $12 million in Seri...citybizlis...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In